Sevelamer Hydrochloride in Peritoneal Dialysis Patients

• Status: Completed
• Trial end date: 2015-01-01
• Target enrollment: 0
• Participant gender: All

Summary

To test the hypothesis that second-line fixed low-dose sevelamer hydrochloride therapy is as effective as first-line high-dose sevelamer hydrochloride therapy in limiting the progression of cardiovascular calcification.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Hong Kong
• Treatments: Sevelamer

Criteria

Inclusion Criteria:

• ESRD patients receiving long-term peritoneal dialysis treatment with hyperphosphatemia currently receiving aluminum-based phosphorus binders or whose phosphorus control remains suboptimal with calcium-based binders only

• Patients who cannot afford to self-pay sevelamer hydrochloride.

• Patients who provided informed consent for the study

Exclusion Criteria:

• Patients with underlying active malignancy

• Patients with cyanotic congenital heart disease

• Patients with poor general condition

• Patients with plan for living related kidney transplant within coming 1 year

• Female patients with pregnancy